Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451

Reuters

2025/09/04

Aptevo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451. These candidates are designed to target prostate cancer and various solid tumor types with significant unmet needs. The development of these trispecific CD3-directed molecules is supported by clinical validation from the lead candidate, mipletamig, which has shown clinical safety and efficacy in treating acute myeloid leukemia (AML). Aptevo's pipeline now includes eight bispecific and trispecific therapeutic candidates, with five utilizing the CRIS-7-derived CD3 pathway. Results of these new developments are anticipated in future studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068686) on September 04, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564637296"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564637296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564637296?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-04 20:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564637296","market":"fut","top_or_hot":-1,"title":"Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a>, a clinical-stage biotechnology company, has announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451. These candidates are designed to target prostate cancer and various solid tumor types with significant unmet needs. The development of these trispecific CD3-directed molecules is supported by clinical validation from the lead candidate, mipletamig, which has shown clinical safety and efficacy in treating acute myeloid leukemia (AML). Aptevo's pipeline now includes eight bispecific and trispecific therapeutic candidates, with five utilizing the CRIS-7-derived CD3 pathway. Results of these new developments are anticipated in future studies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068686) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-04 20:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APVO\">Aptevo Therapeutics Inc.</a>, a clinical-stage biotechnology company, has announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451. These candidates are designed to target prostate cancer and various solid tumor types with significant unmet needs. The development of these trispecific CD3-directed molecules is supported by clinical validation from the lead candidate, mipletamig, which has shown clinical safety and efficacy in treating acute myeloid leukemia (AML). Aptevo's pipeline now includes eight bispecific and trispecific therapeutic candidates, with five utilizing the CRIS-7-derived CD3 pathway. Results of these new developments are anticipated in future studies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068686) on September 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250904:nNDL1DNMfp:1","article_id":"2564637296","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564637296","pubTimestamp":1756989933,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451. Aptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451. These candidates are designed to target prostate cancer and various solid tumor types with significant unmet needs. The development of these trispecific CD3-directed molecules is supported by clinical validation from the lead candidate, mipletamig, which has shown clinical safety and efficacy in treating acute myeloid leukemia . Aptevo's pipeline now includes eight bispecific and trispecific therapeutic candidates, with five utilizing the CRIS-7-derived CD3 pathway. Results of these new developments are anticipated in future studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","EBS":"Emergent Biosolutions","BK4583":"猴痘概念","APVO":"Aptevo Therapeutics Inc."},"translate_title":"Aptevo Therapeutics推出三特异性CD3靶向抗癌分子APVO452和APVO451，扩大肿瘤产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":0.9,"APVO":0.9},"content_text":"Aptevo Therapeutics Expands Oncology Pipeline with Launch of Trispecific CD3-Directed Anti-Cancer Molecules APVO452 and APVO451\n    \n\nAptevo Therapeutics Inc., a clinical-stage biotechnology company, has announced the expansion of its anti-cancer pipeline with the filing of two provisional patents for trispecific candidates, APVO452 and APVO451. These candidates are designed to target prostate cancer and various solid tumor types with significant unmet needs. The development of these trispecific CD3-directed molecules is supported by clinical validation from the lead candidate, mipletamig, which has shown clinical safety and efficacy in treating acute myeloid leukemia (AML). Aptevo's pipeline now includes eight bispecific and trispecific therapeutic candidates, with five utilizing the CRIS-7-derived CD3 pathway. Results of these new developments are anticipated in future studies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1068686) on September 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}